Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study

被引：0
|
作者：
Koenemann, Lisette [1 ]
Htoo, Phyo Than [2 ,3 ]
Patorno, Elisabetta [2 ,3 ]
Tesfaye, Helen [2 ,3 ]
Wexler, Deborah J. [4 ,5 ]
Glynn, Robert J. [2 ,3 ]
Schmedt, Niklas
Deruaz-Luyet, Anouk [6 ]
Schneeweiss, Sebastian [2 ,3 ]
Paik, Julie M. [2 ,3 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] HMS, BWH, Boston, MA USA
[3] Div Pharmacoepidemiol, Boston, MA USA
[4] HMS, MGH, Boston, MA USA
[5] MGH Diabet Ctr, Boston, MA USA
[6] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-09
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 50 条
  • [1] Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease-Results from the EMPRISE Study
    Htoo, Phyo T.
    Patorno, Elisabetta
    Tesfaye, Helen
    Wexler, Deborah J.
    Glynn, Robert
    Schmedt, Niklas
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Paik, Julie M.
    DIABETES, 2023, 72
  • [2] Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
    Htoo, Phyo T.
    Tesfaye, Helen
    Schneeweiss, Sebastian
    Wexler, Deborah J.
    Everett, Brendan M.
    Glynn, Robert J.
    Schmedt, Niklas
    Koeneman, Lisette
    Deruaz-Luyet, Anouk
    Paik, Julie M.
    Patorno, Elisabetta
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [3] Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
    Phyo T. Htoo
    Helen Tesfaye
    Sebastian Schneeweiss
    Deborah J. Wexler
    Brendan M. Everett
    Robert J. Glynn
    Niklas Schmedt
    Lisette Koeneman
    Anouk Déruaz-Luyet
    Julie M. Paik
    Elisabetta Patorno
    Cardiovascular Diabetology, 23
  • [4] Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Bessette, Lily G.
    Najafzadeh, Mehdi
    Wexler, Deborah J.
    Franklin, Jessica
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Koeneman, Lisette
    Schneeweiss, Sebastian
    DIABETES, 2020, 69
  • [5] Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
    Htoo, Phyo T.
    Tesfaye, Helen
    Paik, Julie M.
    Wexler, Deborah J.
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz F. Fazeli
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [6] Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonists among Patients with Type 2 Diabetes
    Pimple, Pratik
    Raju, Aditya
    Farrelly, Eileen
    Shetty, Sharash
    DIABETES, 2021, 70
  • [7] GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
    Abasheva, Daria
    Ortiz, Alberto
    Fernandez-Fernandez, Beatriz
    CLINICAL KIDNEY JOURNAL, 2024, 17 : 19 - 35
  • [8] GLP-1 Receptor Agonists in Diabetic Kidney Disease
    Michos, Erin D.
    Tuttle, Katherine R.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (10): : 1578 - 1580
  • [9] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [10] Cardiovascular effectiveness of empagliflozin compared to DPP4 inhibitors and to GLP1 receptor agonists: Interim analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 119 - 119
12345